Targeted Therapy Agent

Phase 2Small molecule

SShandong Cancer Hospital and Institute

Targeted Therapy Agent is one of 84 small molecule programs targeting Lung Cancer. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Lung CancerActive, not recruiting

Non-Small Cell Lung CancerActive, not recruiting

Colorectal CancerActive, not recruiting

Lung CancerPreclinical

Active, not recruiting

Non-Small Cell Lung CancerPhase 1

Active, not recruiting

Colorectal CancerPhase 2

Active, not recruiting

Competition

Competitive Landscape

1639 competitors in Non-Small Cell Lung Cancer

#DrugCompanyPhaseTrials

Yervoy

Bristol-Myers Squibb

Preclinical

31 2

Gemzar

GGynecologic Oncology Group

Preclinical

72 3

PORTRAZZA

Eli Lilly

Preclinical

8 4

Lenvima

Eisai

Preclinical

6 5

Imjudo

AstraZeneca

Preclinical

5 6

Targeted Therapy Agent

SShandong Cancer Hospital and Institute

Phase 2

1 7

Tyrosine Kinase Inhibitor

Pfizer

Preclinical

2 8

Aqupla

Jiangsu Simcere Pharmaceutical Co., Ltd.

Preclinical

—9

Ftorafur

TThe First Affiliated Hospital with Nanjing Medical University

Preclinical

—10

Vibramycin

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Recruiting

Colorectal Cancer

NCT06356584

Q4 2028

Recruiting

Lung Cancer

NCT06218901

Clinical

Trials by Indication[1]

Non-Small Cell Lung Cancer1 trial

Pamiparib (BGB-290) Was Used in EGFR-TkIs Resistant Non-small Cell Lung Cancer

Unknown status·—·Phase 1·NCT05573373·40 enrolled

Lung Cancer1 trial

Association of Psychological Distress in Patients With Lung Cancer

Recruiting·SShanghai Chest Hospital··NCT06218901·500 enrolled

Colorectal Cancer1 trial

Fruquintinib Combined With Sintilimab ± Radiotherapy for Third-line Treatment of Colorectal Cancer With Liver Metastases

Recruiting·SShandong Cancer Hospital and Institute·Phase 2·NCT06356584·62 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Targeted Therapy Agent. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Targeted Therapy Agent compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Targeted Therapy Agent. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Shandong Cancer Hospital and Institute company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: SShandong Cancer Hospital and Institute

Targeted Therapy Agent

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q4 2028

Trials by Indication[1]

Non-Small Cell Lung Cancer1 trial

Lung Cancer1 trial

Colorectal Cancer1 trial

References

Drug Info

Quick Facts

Related News